WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered ...
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
WUXI, China, May 14, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end ...
WuXi Biologics Completed Three Acquisitions to Enhance its Global Network
SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal,Germany, the Pfizer China ("Pfizer") manufacturing...
WuXi Biologics Receives 2021 Asia-Pacific Bioprocessing Excellence Award from IMAPAC
SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized as the grand winner of the Bioprocessing Excellence inGreater China Region Award in two prestigious cate...
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...
2020 Results Record High Despite a Challenging Year
Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2% Milestone Revenue Surged by 71.7% to US$95 Million Total Backlog up 122.0% to ...
WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group
SUZHOU, China, March 18, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other compani...
WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China
HANGZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art biologics manu...
WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19
SHANGHAI and DUNDALK, Ireland, March 16, 2021 /PRNewswire/ -- WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), today announced it achieved the weather-tight construction milestone of its vaccine manufacturing facility currently under construction ...
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
WuXi Biologics Receives GMP Certification from Brazil's ANVISA
* First company in China to receive GMP certification for the production of biologics from the U.S. FDA, EMA and ANVISA WUXI, China, Dec. 28, 2020 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that ...
WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer
* The DS facility (MFG19) with 3x1000L perfusion and 6x2000L fed-batch capacity for vaccines and biologics is expected to be GMP ready in late 2021 * Complements WuXi Biologics' existing DP capacity in Germany * Capacity expansion allows WuXi Biologics to meet growing client demand worldwide...
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
MUNICH and SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- Tubulis, WuXi STA and WuXi Biologics today announced a strategic collaboration to manufacture and advance Tubulis' next generation antibody-drug conjugates (ADCs) towards IND-enabling studies. Tubulis has developed a dual platform approach to gene...
WuXi Biologics Launched Biologics Integrated Innovation Center in Hangzhou
HANGZHOU, China, Nov. 20, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced its biologics integrated innovation center has been in operation inHangzhou, Zhejiang province, China. From process deve...
WuXi Biologics and AB2 Bio Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
* Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) * WuXi Biologics to undertake commercial-scale manufacturing to support U.S. market launch SHANGHAI and LAUSANNE, Switzerland, Oct. 2...
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
SHANGHAI, Oct. 10, 2020 /PRNewswire/ -- Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics ("WuXi Bio") (2269.HK) a...
WuXi Biologics Records Excellent Interim Results
Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Diluted EPS Up 38.5% Y-o-Y to RMB...
WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer
SHANGHAI and DUNDALK, Ireland, Aug. 6, 2020 /PRNewswire/ -- WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased to announce the appointment of Mr.Jian Dong as Chief Executive Officer (CEO). WuXi Vacci...
